Tweet
Heliyon
. 2024 Nov 1;10(22):e40059.
doi: 10.1016/j.heliyon.2024.e40059. eCollection 2024 Nov 30. Longer duration of high-dose corticosteroids provides benefit for hospitalized COVID-19 patients with high oxygen requirement
Junping Fan 1 , Huaiya Xie 1 , Yaqi Wang 1 , Siqi Pan 1 , Tingyu Wang 2 3 , Chuan Shi 1 , Xinjie Hui 1 , Huan Hou 1 , Xiaoxing Gao 1 , Wangji Zhou 1 , Xiangning Liu 1 , Yunxin Liu 1 , Jinglan Wang 1 , Xinlun Tian 1
Affiliations
The optimal corticosteroids dose in patients with coronavirus disease 2019 (COVID-19) requiring high oxygen remains unknown. In this retrospective study of patients with COVID-19 requiring high oxygen and receiving corticosteroids, the efficacy, safety, and duration of high-dose treatment were evaluated. The primary outcome was all-cause mortality during follow-up. Safety outcomes included infection, gastrointestinal bleeding, and venous thromboembolic events. 210 patients were included, with 126 in Group A (corticosteroids at a equivalent dose <1 mg/kg/d prednisone), 44 in Group B (corticosteroids at a equivalent dose ≥1 mg/kg/d prednisone for ≤5 days), and 40 in Group C (corticosteroids at a equivalent dose ≥1 mg/kg/d prednisone for >5 days). The all-cause mortality risk was lower in Group C but higher in Group B than in Group A. Safety outcomes did not differ significantly, except for Group C, which had the highest venous thromboembolism rate. Our results suggest that high-dose corticosteroids for a longer course decrease mortality with comparable safety outcome.
Keywords: COVID-19; Corticosteroids; Duration; High oxygen requirement.
. 2024 Nov 1;10(22):e40059.
doi: 10.1016/j.heliyon.2024.e40059. eCollection 2024 Nov 30. Longer duration of high-dose corticosteroids provides benefit for hospitalized COVID-19 patients with high oxygen requirement
Junping Fan 1 , Huaiya Xie 1 , Yaqi Wang 1 , Siqi Pan 1 , Tingyu Wang 2 3 , Chuan Shi 1 , Xinjie Hui 1 , Huan Hou 1 , Xiaoxing Gao 1 , Wangji Zhou 1 , Xiangning Liu 1 , Yunxin Liu 1 , Jinglan Wang 1 , Xinlun Tian 1
Affiliations
- PMID: 39605841
- PMCID: PMC11600092
- DOI: 10.1016/j.heliyon.2024.e40059
The optimal corticosteroids dose in patients with coronavirus disease 2019 (COVID-19) requiring high oxygen remains unknown. In this retrospective study of patients with COVID-19 requiring high oxygen and receiving corticosteroids, the efficacy, safety, and duration of high-dose treatment were evaluated. The primary outcome was all-cause mortality during follow-up. Safety outcomes included infection, gastrointestinal bleeding, and venous thromboembolic events. 210 patients were included, with 126 in Group A (corticosteroids at a equivalent dose <1 mg/kg/d prednisone), 44 in Group B (corticosteroids at a equivalent dose ≥1 mg/kg/d prednisone for ≤5 days), and 40 in Group C (corticosteroids at a equivalent dose ≥1 mg/kg/d prednisone for >5 days). The all-cause mortality risk was lower in Group C but higher in Group B than in Group A. Safety outcomes did not differ significantly, except for Group C, which had the highest venous thromboembolism rate. Our results suggest that high-dose corticosteroids for a longer course decrease mortality with comparable safety outcome.
Keywords: COVID-19; Corticosteroids; Duration; High oxygen requirement.